Press release: Linguamatics’ I2E Text Mining Platform Chosen by FDA
Linguamatics
CDER to use Linguamatics I2E in support of drug safety research activities
(Cambridge, England and Boston, USA – August 1st 2012)
Linguamatics, the leader in natural language processing (NLP)-based text mining, announced today that the FDA’s Center for Drug Evaluation and Research (CDER) has licensed its I2E text mining platform to support laboratory research efforts on drug safety. Financial details of the agreement were not disclosed.
During the term of the license, CDER will use I2E to mine published literature and drug product labels to answer questions relating to a range of biomedical topics, including drug toxicity mechanisms and disease processes.
I2E’s NLP-based querying capabilities, coupled with its scalability and flexibility, mean it is ideally suited to answering many challenging, high value questions in life sciences and healthcare by unlocking knowledge buried in the scientific literature and other textual information. Rather than just retrieving documents, I2E can rapidly identify, extract, synthesize and analyze specific, relevant facts and relationships, such as those between genes and diseases or compounds and side effects. Customers include nine of the top ten global pharmaceutical companies.
“We are very pleased to welcome CDER/FDA as a customer”, commented John Brimacombe, Executive Chairman at Linguamatics. “Their adoption of the I2E text mining platform reflects the continued growth in demand for NLP-based text mining as a key knowledge discovery and decision support tool in the pharmaceutical, biotechnology and healthcare sectors.”